Intranasal Ketamine in Treatment-Resistant Depression

The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).

Topic Depression
Compound Placebo Ketamine
Country United States of America
Visit trial
Status Completed
Results Published
Start date 10 January 2011
End date 10 January 2014
Phase Not Applicable
Design Blinded
Type Interventional
Generation First
Participants 20
Sex All
Age 21- 65
Therapy No

Trial Details

The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).

Trial Number NCT01304147

Sponsors & Collaborators

Icahn School of Medicine at Mount Sinai
This company doesn't have a full profile yet, it is linked to a clinical trial.

Measures Used

Montgomery-Asberg Depression Rating Scale
A ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.